



Shifting **THE PARADIGM** of Melanoma Treatment

CLARADELE
PHARMACEUTICALS

Presented by:

Eric Hacherl, Ph. D.
Chief Executive Officer

The Problem


**Melanoma is the most lethal skin cancer —
and is among the fastest-rising cancer burdens.**

— RISING GLOBAL IMPACT —

~325,000
new cases
annually

~57,000
deaths
worldwide

Expected
to double
by 2040



Even with checkpoint inhibitors, ~50% of melanoma patients fail to respond—representing a **\$184M–\$1.26B target segment.**


**~50% = No Effect
on Tumor Growth**

★ **OPPORTUNITY**

The Solution

PMJ2: A novel small-molecule immunotherapy that restores sensitivity to checkpoint inhibitors.

Active Site



VALIDATED
PRECLINICAL RESULTS

REPROGRAMS
THE TUMOR
MICROENVIRONMENT


ENHANCES
CHECKPOINT INHIBITOR
EFFICACY

NON-VIRAL, SCALABLE
APPROACH

Tumor cell death + immune activation + potential CPI re-sensitization

PMJ2 Demonstrates Tumor Control + Durable Immune Response


TUMOR CONTROL via ER stress



**PMJ2
suppressed
tumor growth
by >70%**


ER stress (CHOP10) +
apoptosis (TUNEL)

DURABLE IMMUNE RESPONSE Memory T-cell response



Significantly increased memory T-cell
infiltration after tumor rechallenge

Growing Market, Unmet Medical Need



\$5.8B → \$10.3B TOTAL AVAILABLE MARKET (TAM)

- ~10% CAGR through 2030 + 4–6% incidence growth in key markets

\$184M–\$1.26B SERVICEABLE AVAILABLE MARKET (SAM)

- 20K–40K CPI non-responders/progressors annually

3K–10K/year TARGET PATIENT POPULATION (SOM)

- 15–25% of SAM

Competitive Landscape: Closest Products, Approved or Pipeline

Cell Therapy

Amtagvi

- ✓ High efficacy in responders
- ✗ 6-week mfg; limited eligibility

Oncolytic Virus

T-VEC

- ✓ Intralesional
- ✓ Immune activation
- ✗ Viral safety
- ✗ Modest efficacy as monotherapy

Checkpoint Combos

Yervoy+Opdivo

- ✓ Established efficacy
- ✗ Limited after acquired resistance
- ✗ ~50% of patients fail to respond

PMJ2 Advantage

Claradele

- ✓ Small molecule
- ✓ Intralesional
- ✓ ER stress mechanism
- ✓ Faster, scalable access
- ✓ DAMP/Immune activation data

Differentiated ER stress/DAMP approach for potential CPI re-sensitization

Partnership-Driven Exit Strategy

Partner at the value inflection point

Phase Ib/IIa out-license after early efficacy signal

Strategic fit

Checkpoint inhibitor franchises and melanoma infrastructure

Why PMJ2?

Expand the value of existing CPI portfolios by addressing non-response and resistance

IND-ready 2028

Early efficacy 2029–30

Partner / Out-license 2030–31

Target economics: \$3M upfront + \$100–425M milestones + ~11% royalty

Our Business & Regulatory Team

Experienced Leadership Driving Oncology Innovation and Commercial Translation



Stella Vnook, Ph.D.
Chair/Independent
Director

Seasoned pharmaceutical executive with 25+ years leading biotech companies through growth, acquisition, and commercialization.



Rukiyah Van Dross, Ph.D.
Founder, Director,
Chief Scientific Officer

Inventor of PMJ2 and principal investigator on NIH- and NC-funded melanoma immunotherapy programs.



Eric Hacherl, Ph.D.
Director, Chief
Executive Officer

Biopharma business development leader with expertise in early-stage fundraising, strategic partnerships, and GTM strategy for emerging therapeutics.



Gerald Klein, MD
Chief Medical
Officer

Oncology drug development veteran with 25+ years of experience leading clinical and regulatory strategy for early-phase cancer trials.



Colin Burns, Ph.D.
Product
Development

Organic chemist with 13+ years developing and optimizing PMJ2 synthesis, production scale-up, and analytical characterization methods.

BOARD OF DIRECTORS

Seeking
strategic
partners to
help achieve
IND submission
by Q3 2028

Advancing PMJ2 to the Clinic

BUILD ON OUR MOMENTUM

\$1.8M raised to date in
non-dilutive funding

REACH THE NEXT MILESTONE

GLP tox + IND-enabling studies =
IND submission

WAYS TO ENGAGE

- Scientific & clinical expertise
- Strategic introductions & partnerships
- Development resources
- Investment / capital

OUR MISSION:

To transform the treatment landscape for melanoma by addressing resistance to immunotherapy.

OUR BREAKTHROUGH:

PMJ2 — a first-in-class small-molecule immunotherapy designed to enhance the effectiveness of checkpoint inhibitors.

OUR VISION:

To deliver better outcomes for patients and create new value in the melanoma immunotherapy market.

RECOGNITION & STRATEGIC PARTNERS:



CLARADELE
PHARMACEUTICALS

CONTACT

Eric Hacherl



eric@claradele.com

www.Claradele.com

[follow us on LinkedIn](#)